

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Daiichi Sankyo Launches Measles and Rubella Vaccine “Kitasato Daiichi Sankyo” in Japan

TOKYO, Japan (May 24, 2011) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today launched its measles and rubella vaccine, Kitasato Daiichi Sankyo (standard name: freeze-dried live attenuated measles and rubella combined vaccine), in Japan.

This vaccine is a combination of the live measles vaccine, Kitasato Daiichi Sankyo (AIK-C strain), and a freeze-dried live attenuated rubella vaccine (Takahashi strain). There are no effective treatments for measles or rubella and vaccination is the only way to prevent infection. Because of the convenience this vaccine offers in preventing measles and rubella through one injection, and consequently the small physical burden on young children, Daiichi Sankyo expects immunization rates to increase.

The Daiichi Sankyo Group strives to meet vaccine needs through a supply of drugs to improve public hygiene and bolster immunization initiatives in order to contribute to a healthy society.

Product Overview

Launch date: May 24, 2011

Product name	Measles and rubella vaccine Kitasato Daiichi Sankyo
Biological product Standard name	Freeze-dried live attenuated measles and rubella combined vaccine (AIK-C strain, Takahashi strain)
Efficacy	Prevention of measles and rubella
Dosage	Dissolve in 0.7 ml of packaged solvent (water for injection), administer subcutaneous injection of 0.5 ml
Manufacture and sales	Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Sales	Daiichi Sankyo Company Ltd.